Pan-Cancer / PANCAN (TCGA PanCancer Atlas)
Overview
PANCAN is not an OncoTree cancer-type code but is used in this wiki as a corpus identifier for studies that span all 33 TCGA cancer types in the PanCancer Atlas. It indicates findings that are genuinely pan-cancer in scope rather than specific to any single tumor type. The TCGA PanCancer Atlas comprises ~10,000–11,000 tumor samples analyzed uniformly across molecular platforms.
Cohorts in the corpus
- TCGA PanCancer Atlas: 33 cancer types analyzed jointly across somatic mutation (MC3), RNA-seq, copy number (SNP6/ABSOLUTE), and methylation platforms.
- Reference datasets: gbm_tcga_pan_can_atlas_2018, coadread_tcga_pan_can_atlas_2018, cesc_tcga_pan_can_atlas_2018, and equivalent study slugs for all 33 disease types.
Recurrent alterations
- Pan-cancer fusion study (9,624 TCGA samples, 33 cancer types) identified 25,664 fusions with 63.3% WGS validation rate; 6.0% of pan-cancer samples harbor at least one druggable fusion; fusions are the sole driver in ~1.8% of tumors; TP53 is predominantly mutated rather than fused across cancer types PMID:29617662.
Subtypes
- Each of the 33 TCGA cancer types is a subtype of the PANCAN scope; see individual cancer-type pages for disease-specific findings.
Therapeutic landscape
Sources
- PMID:29617662 — Pan-cancer fusion landscape (Gao et al., 2018)
This page was processed by crosslinker on 2026-05-15.